Valsartan GPO

Valsartan GPO





Concise Prescribing Info
HTN alone or in combination w/ other anti-hypertensive agents. Heart failure (NYHA Class II-IV). Reduce CV mortality in clinically stable patients w/ left ventricular failure or left ventricular dysfunction following MI.
Dosage/Direction for Use
HTN Adult Usual dose: 80-320 mg once daily. Max dose: 320 mg daily. Patients who are not vol depleted As monotherapy: Initially 80 or 160 mg once daily. Patients requiring greater reductions may be started at a higher dose. Dose adjustment: May be increased to a max of 320 mg/day or a diuretic may be added. Childn 6-16 yr Initial dose: 1.3 mg/kg once daily (up to 40 mg in total). Dose adjustment: Adjust dose according to BP response. Max: 2.7 mg/kg (up to 160 mg). Heart failure Adult Initial dose: 40 mg bid. Max dose: 320 mg/day. Dose titration: Up titration to 80 & 160 mg bid should be done to the highest dose as tolerated. Post-MI Initially 20 mg bid as early as 12 hr after an MI. Dose titration: May be up-titrated w/in 7 days to 40 mg bid w/ subsequent titration to a target maintenance dose of 160 mg bid.
May be taken with or without food.
Hypersensitivity. Do not co-administer w/ aliskiren in patients w/ DM.
Special Precautions
Patients who are intravascularly vol depleted (eg, those treated w/ diuretics); correct these conditions prior to administration. Hyperkalemia in patients w/ heart failure & preexisting renal impairment. Renal dysfunction, DM or concomitant use of K-sparing diuretics, K-supplements &/or K-containing salts. Hypotension may occur during major surgery & anesth. Patients w/ significant aortic/mitral stenosis; unstented unilateral/bilateral renal artery stenosis; preexisting renal insufficiency; obstructive biliary disease or hepatic impairment. Avoid concomitant use w/ aliskiren in patients w/ glomerular filtration rate <60 mL/min & contraindicated in patients w/ DM. Acute renal failure may occur; withhold or discontinue therapy in patients who develop decrease renal function. Do not re-administer to patients w/ a history of angioedema. Discontinue therapy if angioedema occurs. Pregnancy (discontinue treatment) & lactation. Ped patients <6 yr.
Adverse Reactions
Dizziness, fatigue, headache; abdominal pain, diarrhea, nausea/vomiting; arthralgia; cough, pharyngitis, rhinitis, sinusitis, upper resp tract infection; edema, viral infection.
Drug Interactions
May increase the serum conc of ACE inhibitors. Hypotensive effect may be enhanced w/ alfuzosin, other antihypertensives, barbiturates, dapoxetine, diazoxide, herb (hypotensive properties), hydrochlorothiazide, MAOIs, pentoxifylline, prostacyclin analogues. May enhance hyperkalemia/hypotensive/nephrotoxic effect w/ aliskiren. May enhance hypotensive effect of amifostine, obinutuzumab, risperidone, rituximab. May enhance hypertensive effect w/ brimonidine (topical). May enhance hyperkalemic/hypotensive effect w/ canagliflozin. May enhance arrhythmogenic effect of ciprofloxacin. May enhance hyperkalemic effect w/ cyclosporine, eplerenone, heparin (including low molecular wt heparin), nicorandil, K salts, K-sparing diuretics, tolvaptan, trimethoprim. May increase serum conc of eltrombopag, lithium, teriflunomide. May diminish antihypertensive effect w/ herbs (hypertensive properties), methylphenidate, & yohimbine. May enhance adverse/toxic effects of other hypotensive agents, NSAIDs. May enhance orthostatic hypotensive effect of levodopa. May enhance hypotensive/orthostatic hypotensive effect w/ MAIOs. May enhance antihypertensive effect w/ phosphodiesterase 5 inhibitors. May enhance nephrotoxic effect of Na phosphates.
ATC Classification
C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Valsartan GPO FC tab 160 mg
3 × 10's
Valsartan GPO FC tab 80 mg
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in